Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Adcetris

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

- PMLiVE

Lilly buoyant as lung cancer hope clears pivotal study

Necitumumab on course for regulatory submission in 2014

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

- PMLiVE

Vical’s cancer immunotherapy fails in late-stage trial

Allovectin no better than standard chemotherapy

Roche - Basel

Roche’s Erivedge authorised in UK

Available for skin cancer patients through Cancer Drugs Fund

- PMLiVE

GSK submits Votrient for ovarian cancer in Europe

Pharma company hopes for extra indication for oncology product

Novartis building

Novartis says Afinitor fails liver cancer trial

Halts plans to file for approval in new indication

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

Bayer symbol

Bayer to research cancer immunotherapies with Compugen

Will develop drugs that boost response of body’s immune system to tumours

- PMLiVE

Pfizer sales dip as net income surges in Q2

Lipitor performance weighs heavy on the figures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links